Zynerba: Clinical Update; Announces Two New Clinical Indications

– Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome –

– Cash Runway Now Extends into the Second Half of 2020 –

– Conference Call to be Held Today at 8:30 am Eastern Time –

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its clinical progress.

• Zynerba remains on track to report top line results from the CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) study in Fragile X Syndrome in the second half of 2019;
• The Company has completed enrollment in its Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial in children and adolescents with developmental and epileptic encephalopathies (DEE). Top-line results will be reported in the third quarter of 2019;
• Zynerba has expanded its pipeline with the addition of two new childhood neuropsychiatric clinical targets for ZYN002: Autism Spectrum Disorder (ASD) and 22q11.2 Deletion Syndrome (22q Deletion Syndrome; 22q), a rare genetic syndrome leading to significant impairments, including neuropsychiatric disorders. The Company expects to initiate open label Phase 2 studies in these indications in the first half of 2019 and report top-line results in first half 2020;
• The Company has postponed the initiation of its clinical trial in adult epilepsy until after the completion of the four childhood neuropsychiatric studies; and
• As a result, Zynerba expects to extend its cash runway into the second half of 2020.

“Our aspirations and expectations are clear: To work closely with the U.S. Food and Drug Administration to expand the opportunity for pharmaceutically-developed CBD treatments that meet their rigorous medical and manufacturing standards, and in doing so, continue toward our goal of addressing significant unmet medical needs in neuropsychiatric disorders,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “With the new indications of ASD and 22q, in addition to FXS and DEE, we now have four shots on goal to show the clinical benefit of ZYN002 transdermal gel in patient populations that have few, if any, therapeutic options available.”

Conference call information
Zynerba management will host a live conference call and webcast today at 8:30 am Eastern Standard Time to provide a corporate update. The call can be accessed by dialing (866) 573-0180 (U.S. and Canada) or (430) 775-1345 (international) and referencing conference ID 6892856. To access the live webcast or the replay, visit the investor page of the Company’s website at http://ir.zynerba.com/. The webcast will be recorded and available on the Company’s website for 30 days.

https://www.marketscreener.com/ZYNERBA-PHARMACEUTICALS-I-23277306/news/Zynerba-Pharmaceuticals-Provides-Clinical-Update-and-Announces-Two-New-Clinical-Indications-27762648/